SCHEMBL3250865

SCHEMBL3250865

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Nc4ccc(OC)cc4)cc3c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.50
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPK1 P28482 2/20 0.50
ALOX15 P16050 2/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALOX12 P18054 1/20 0.49
POLB P06746 7/20 0.48
BRD4 O60885 1/20 0.48
BACE1 P56817 1/20 0.48
TP53 P04637 8/20 0.48
MAPT P10636 8/20 0.48
LMNA P02545 5/20 0.48
USP2 O75604 1/20 0.47
THRB P10828 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254038 0.95 BRD4 (0.55) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3241955 0.92 MAPT (0.53) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3252031 0.91 PKM (0.53) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3251351 0.91 MEN1 (0.61) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3250340 0.91 ALDH1A1 (0.55) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3249007 0.90 HSD17B10 (0.51) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3244722 0.90 PKM (0.56) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3252629 0.90 HSD17B10 (0.51) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3254789 0.90 PKM (0.51) HSD17B10ALDH1A1HPGDMEN1KMT2A
SCHEMBL3247530 0.89 HSD17B10 (0.48) HSD17B10ALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HSD17B10 3847/4885ALDH1A1 3830/4885HPGD 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.